Literature DB >> 12198702

The APC tumor suppressor controls entry into S-phase through its ability to regulate the cyclin D/RB pathway.

Christopher D Heinen1, Kathleen Heppner Goss, James R Cornelius, George F Babcock, Erik S Knudsen, Timothy Kowalik, Joanna Groden.   

Abstract

BACKGROUND & AIMS: APC gene mutation is an early alteration in most colorectal tumors. In an attempt to determine its role in tumor development, we asked whether reintroducing wild-type APC into colorectal cancer cells with mutant APC affected cell cycle progression.
METHODS: Using transient transfection, a plasmid containing the APC complementary DNA and DNA encoding the green fluorescent protein was expressed in SW480 cells. In addition, several other constructs were co-expressed with APC to determine their combined effects.
RESULTS: We report that colorectal cancer cell lines transfected with wild-type APC arrest in the G(1)- phase of the cell cycle and that this arrest is abrogated by cotransfecting constitutively active beta-catenin or cyclin D1 and cMYC together. This APC-induced cell cycle arrest involves the disruption of beta-catenin-mediated transcription and depends on components of the G(1)/S regulatory machinery, as overexpression of E1a or E2F-1, -2, or -3 overrides the G(1) arrest. Consistent with this, APC transfection inhibits RB phosphorylation and reduces levels of cyclin D1.
CONCLUSIONS: Our results suggest that APC functions upstream of RB in the G(1)/S regulatory pathway, cyclin D1 and cMYC affect APC-mediated arrest equivalently to oncogenic beta-catenin, and most colon tumors disrupt control of G(1)/S progression by APC mutation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12198702     DOI: 10.1053/gast.2002.35382

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  32 in total

Review 1.  APC as a checkpoint gene: the beginning or the end?

Authors:  Vincent W Yang
Journal:  Gastroenterology       Date:  2002-09       Impact factor: 22.682

Review 2.  Functions of the APC tumor suppressor protein dependent and independent of canonical WNT signaling: implications for therapeutic targeting.

Authors:  William Hankey; Wendy L Frankel; Joanna Groden
Journal:  Cancer Metastasis Rev       Date:  2018-03       Impact factor: 9.264

3.  Haploinsufficiency of Krüppel-like factor 4 promotes adenomatous polyposis coli dependent intestinal tumorigenesis.

Authors:  Amr M Ghaleb; Beth B McConnell; Mandayam O Nandan; Jonathan P Katz; Klaus H Kaestner; Vincent W Yang
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

4.  The APC tumor suppressor inhibits DNA replication by directly binding to DNA via its carboxyl terminus.

Authors:  Jiang Qian; Amod A Sarnaik; Tera M Bonney; Jeremy Keirsey; Kelly A Combs; Kira Steigerwald; Samir Acharya; Gregory K Behbehani; Michelle C Barton; Andrew M Lowy; Joanna Groden
Journal:  Gastroenterology       Date:  2008-04-04       Impact factor: 22.682

Review 5.  Multiple Roles of APC and its Therapeutic Implications in Colorectal Cancer.

Authors:  Lu Zhang; Jerry W Shay
Journal:  J Natl Cancer Inst       Date:  2017-08-01       Impact factor: 13.506

6.  Global gene expression analysis in time series following N-acetyl L-cysteine induced epithelial differentiation of human normal and cancer cells in vitro.

Authors:  Anna C Gustafsson; Ilya Kupershmidt; Esther Edlundh-Rose; Giulia Greco; Annalucia Serafino; Eva K Krasnowska; Thomas Lundeberg; Luisa Bracci-Laudiero; Maria-Concetta Romano; Tiziana Parasassi; Joakim Lundeberg
Journal:  BMC Cancer       Date:  2005-07-07       Impact factor: 4.430

7.  Topoisomerase IIalpha binding domains of adenomatous polyposis coli influence cell cycle progression and aneuploidy.

Authors:  Yang Wang; Robert J Coffey; Neil Osheroff; Kristi L Neufeld
Journal:  PLoS One       Date:  2010-04-02       Impact factor: 3.240

8.  The deubiquitinase USP28 controls intestinal homeostasis and promotes colorectal cancer.

Authors:  Markus E Diefenbacher; Nikita Popov; Sophia M Blake; Christina Schülein-Völk; Emma Nye; Bradley Spencer-Dene; Laura A Jaenicke; Martin Eilers; Axel Behrens
Journal:  J Clin Invest       Date:  2014-06-24       Impact factor: 14.808

9.  Nitric oxide-donating aspirin inhibits beta-catenin/T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear beta-catenin-TCF association.

Authors:  Niharika Nath; Khosrow Kashfi; Jie Chen; Basil Rigas
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-17       Impact factor: 11.205

Review 10.  Genotype to phenotype: analyzing the effects of inherited mutations in colorectal cancer families.

Authors:  Christopher D Heinen
Journal:  Mutat Res       Date:  2009-09-17       Impact factor: 2.433

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.